XPO6

Across TCGA pan-cancer cohorts, XPO6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated XPO6 data layer compared with 29 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher XPO6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated XPO6 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where XPO6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.839	0.579	<.001	44	view →
LUAD	DFS	Median	II,III,IV	0.987	0.719	<.001	40	view →
PDAC	OS	Quartile	II,III,IV	0.485	0.934	.007	25	view →
CCRCC	DFS	Median	III,IV	0.067	0.985	.014	19	view →
UCEC	DFS	Median	All	0.857	0.944	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

XPO6–LSCC (DFS)

Open the LSCC breakdown →